Theriva Biologics narrows Q2 2026 net loss to $3.2 million from $13.1 million
Theriva Biologics reported a second-quarter 2026 net loss of $3.2 million, or $0.07 per share, compared with $13.1 million, or $1.93 per share, a year earlier. The company reported no license revenue in the quarter, and the drop in losses came mainly from lower general and administrative expenses. Cash and cash equivalents were $11.3 million at June 30, 2026, and the company said that cash runway extends into Q1 2027.
Key points
- Q2 2026 net loss was $3.2 million, versus $13.1 million in Q2 2025; loss per share was $0.07, versus $1.93
- General and administrative expenses fell 82% to $2.0 million, mainly because of a $9.2 million contingent consideration charge in the prior-year quarter
- Research and development expenses fell 35% to $1.3 million
- Cash and cash equivalents were $11.3 million at June 30, 2026, down $1.7 million from December 31, 2025, with runway into Q1 2027
The filing
Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.